TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Hold" by Brokerages

Key Points

• TransMedics Group has a consensus analyst rating of “Hold” from 13 brokerages, with seven hold ratings and six buy ratings. The average 1-year price target is $134.00.
• Several analysts cut price targets or downgraded the stock recently, including Piper Sandler, Canaccord Genuity, Oppenheimer, Stifel Nicolaus, and Needham. The adjustments reflect a more cautious near-term outlook despite some continued buy ratings.
• The company missed earnings expectations in its latest quarterly report, posting EPS of $0.30 versus the expected $0.62, while revenue rose 21.2% year over year to $173.93 million. Shares were trading well below their 52-week high, opening at $67.53 versus a high of $156.00.

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) have been assigned a consensus recommendation of "Hold" from the thirteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $134.00.

A number of equities analysts have recently weighed in on the stock. Piper Sandler reduced their price target on shares of TransMedics Group from $160.00 to $120.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 6th. Canaccord Genuity Group reduced their price target on shares of TransMedics Group from $152.00 to $124.00 and set a "buy" rating on the stock in a research report on Wednesday, May 6th. Oppenheimer cut shares of TransMedics Group from an "outperform" rating to a "market perform" rating in a research report on Wednesday, May 6th. Stifel Nicolaus reduced their price target on shares of TransMedics Group from $85.00 to $75.00 and set a "hold" rating on the stock in a research report on Tuesday, May 26th. Finally, Needham & Company LLC reduced their price target on shares of TransMedics Group from $174.00 to $142.00 and set a "buy" rating on the stock in a research report on Wednesday, May 6th.

Insider Transactions at TransMedics Group

In other news, CFO Gerardo Hernandez sold 7,236 shares of TransMedics Group stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $147.21, for a total transaction of $1,065,211.56. Following the transaction, the chief financial officer directly owned 14,689 shares of the company's stock, valued at $2,162,367.69. This trade represents a 33.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Stephanie Lovell sold 1,193 shares of TransMedics Group stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $149.62, for a total transaction of $178,496.66. Following the transaction, the director directly owned 2,866 shares in the company, valued at approximately $428,810.92. This represents a 29.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 12,000 shares of company stock valued at $1,768,002 over the last three months. 6.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Harvest Fund Management Co. Ltd acquired a new stake in shares of TransMedics Group during the third quarter worth $29,000. Optiver Holding B.V. raised its holdings in shares of TransMedics Group by 248.1% during the third quarter. Optiver Holding B.V. now owns 268 shares of the company's stock worth $30,000 after acquiring an additional 191 shares during the period. North Star Investment Management Corp. acquired a new stake in shares of TransMedics Group during the first quarter worth $30,000. Ascentis Independent Advisors acquired a new stake in shares of TransMedics Group during the first quarter worth $30,000. Finally, Allworth Financial LP raised its holdings in shares of TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company's stock worth $30,000 after acquiring an additional 113 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Price Performance

Shares of TMDX stock opened at $67.53 on Tuesday. TransMedics Group has a 52-week low of $60.10 and a 52-week high of $156.00. The stock has a market cap of $2.33 billion, a PE ratio of 15.35 and a beta of 1.92. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.19 and a current ratio of 6.74. The firm's 50 day moving average price is $92.00 and its two-hundred day moving average price is $118.27.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The business had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. During the same period in the previous year, the business posted $0.70 earnings per share. TransMedics Group's revenue was up 21.2% compared to the same quarter last year. As a group, analysts forecast that TransMedics Group will post 1.98 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.